Physical Activity Limitations In Children With Severe Haemophilia A. Does Emicizumab Make A Difference?

Ahmed Sobhi Hassan1, Laila Metwally Sherief2, Mona Hamdy3

  • 1Department of Pediatrics, Kafrelsheikh University,Egypt.

Insights

Emicizumab prophylaxis significantly improved physical activity in children with severe haemophilia A. This treatment enhanced the quality of life for young patients managing this rare bleeding disorder.

Area of Science:

  • Paediatric Haematology
  • Clinical Paediatrics
  • Pharmacology

Background:

  • Severe haemophilia A impacts children's physical activity and quality of life.
  • Current treatments aim to prevent bleeding episodes and improve patient outcomes.
  • Emicizumab offers a novel prophylactic option for severe haemophilia A.

Purpose of the Study:

  • To evaluate the impact of emicizumab prophylaxis on physical activity levels in children with severe haemophilia A.
  • To assess changes in physical activity using the Paediatric Haemophilia Activities List.
  • To determine the efficacy of emicizumab in improving daily functioning for these patients.

Main Methods:

  • Prospective cohort study conducted between October 2021 and April 2022.
  • Involved 29 children (aged 4-18 years) with severe haemophilia A receiving emicizumab prophylaxis.
  • Physical activity assessed at baseline and after six months using the Paediatric Haemophilia Activities List.

Main Results:

  • A significant increase in the Paediatric Haemophilia Activities List sum score was observed post-intervention (median 59.54 to 84, p<0.001).
  • The study included 29 boys, with a mean age of 8.7 years.
  • 58.62% of patients were negative for inhibitors.

Conclusions:

  • Emicizumab prophylaxis demonstrated a significant improvement in physical activity levels for children with severe haemophilia A.
  • This suggests emicizumab can positively impact the functional capacity and well-being of young patients.
  • Further research can explore long-term effects and broader quality-of-life improvements.
Abstract

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Exercise and Cardiac Output01:17

Exercise and Cardiac Output

Regular physical activity is essential for maintaining cardiovascular health, with aerobic exercises being particularly effective. According to the American Heart Association, 150 minutes of moderate to intense aerobic exercise per week is recommended for a healthy heart. Aerobic activities may include brisk walking, running, bicycling, cross-country skiing, and swimming, ideally performed three to five times per week.
Sustained exercise increases the muscles' oxygen demand, which can be met...